Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice

BACKGROUND: Immunotherapy with anti-disialoganglioside dinutuximab has improved survival for children with high-risk neuroblastoma (NB) when given after induction chemotherapy and surgery. However, disease recurrence and resistance persist. Dinutuximab efficacy has not been evaluated when initiated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zobel, Michael John, Zamora, Abigail K, Wu, Hong-wei, Sun, Jianping, Lascano, Danny, Malvar, Jemily, Wang, Larry, Sheard, Michael A, Seeger, Robert C, Kim, Eugene S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751216/
https://www.ncbi.nlm.nih.gov/pubmed/33428582
http://dx.doi.org/10.1136/jitc-2020-001560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751216/
https://www.ncbi.nlm.nih.gov/pubmed/33428582
http://dx.doi.org/10.1136/jitc-2020-001560

Ejemplares similares